Skip to content
10-Q

Quarterly Report

G1 THERAPEUTICS, INC.

0001628280-23-026769

← back to feed
Filed
Aug 2, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · Jul 28, 2023 51.75M sh
Capex Q2 2023 · Jun 30, 2023 $0
Capex Q2 2023 · Jun 30, 2022 $506K
Cash And Equivalents Q2 2023 · Jun 30, 2023 $55.91M
Cash And Equivalents Q2 2023 · Dec 31, 2022 $94.59M
Current Liabilities Q2 2023 · Jun 30, 2023 $33.91M
Current Liabilities Q2 2023 · Dec 31, 2022 $35.59M
Total Liabilities Q2 2023 · Jun 30, 2023 $90.34M
Total Liabilities Q2 2023 · Dec 31, 2022 $119.22M
Current Assets Q2 2023 · Jun 30, 2023 $140.44M
Current Assets Q2 2023 · Dec 31, 2022 $179.5M
Total Assets Q2 2023 · Jun 30, 2023 $147.89M
Total Assets Q2 2023 · Dec 31, 2022 $187.97M
Shares Diluted Q2 2023 · Jun 30, 2022 42.71M sh
Shares Diluted Q2 2023 · Jun 30, 2022 42.7M sh
Operating Cash Flow Q2 2023 · Jun 30, 2022 −$76.74M
Stockholders Equity Q2 2023 · Jun 30, 2022 $66.33M
Stockholders Equity Q2 2023 · Mar 31, 2022 $100.13M
Stockholders Equity Q2 2023 · Dec 31, 2021 $143.54M
Eps Diluted Q2 2023 · Jun 30, 2022 −$0.92
Eps Diluted Q2 2023 · Jun 30, 2022 −$2.08
Eps Basic Q2 2023 · Jun 30, 2022 −$0.92
Eps Basic Q2 2023 · Jun 30, 2022 −$2.08
Sga Expense Q2 2023 · Jun 30, 2022 $25.72M
Sga Expense Q2 2023 · Jun 30, 2022 $52.43M
Rd Expense Q2 2023 · Jun 30, 2022 $20.84M
Rd Expense Q2 2023 · Jun 30, 2022 $47.15M
Net Income Q2 2023 · Jun 30, 2022 −$39.45M
Net Income Q2 2023 · Jun 30, 2022 −$88.64M
Net Income Q2 2023 · Mar 31, 2022 −$49.19M
Operating Income Q2 2023 · Jun 30, 2022 −$36.96M
Operating Income Q2 2023 · Jun 30, 2022 −$83.74M
Revenue Q2 2023 · Jun 30, 2022 $10.57M
Revenue Q2 2023 · Jun 30, 2022 $17.48M